nach oben

Supportive Care in Cancer

Erschienen in:

10.02.2018 | Original Article

Exercise capacity and cancer-specific quality of life following curative intent treatment of stage I–IIIA lung cancer

verfasst von: Duc Ha, Andrew L. Ries, Peter J. Mazzone, Scott M. Lippman, Mark M. Fuster

Erschienen in: Supportive Care in Cancer | Ausgabe 7/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Lung cancer survivors are at risk for health impairments resulting from the effects and/or treatment of lung cancer and comorbidities. Practical exercise capacity (EC) assessments can help identify impairments that would otherwise remain undetected. In this study, we characterized and analyzed the association between functional EC and cancer-specific quality of life (QoL) in lung cancer survivors who previously completed curative intent treatment.

Methods

In a cross-sectional study of 62 lung cancer survivors who completed treatment ≥ 1 month previously, we assessed functional EC with the 6-min walk distance (6MWD) and cancer-specific QoL with the European Organization for Research and Treatment of Cancer QoL Questionnaire Core 30 (EORTC-QLQ-C30). Cancer-specific QoL was defined using a validated composite EORTC-QLQ-C30 summary score. Univariable (UVA) and multivariable linear regression analyses (MVA) were performed to assess the relationship between functional EC and cancer-specific QoL.

Results

Lung cancer survivors had reduced functional EC (mean 6MWD = 335 m, 65% predicted) and QoL (mean EORTC-QLQ-C30 summary score = 77, scale range 0–100). In UVA, 6MWD was significantly associated with cancer-specific QoL (R² = 0.16, p = 0.001). In MVA, in a final model that also included heart failure, obstructive sleep apnea, and psychiatric illness, 6MWD was independently associated with cancer-specific QoL (partial R² = 0.20, p = 0.001).

Conclusions

Functional EC was independently associated with cancer-specific QoL in lung cancer patients postcurative intent treatment. Exercise-based interventions aimed at improving EC may improve cancer-specific QoL in these patients.

Nur mit Berechtigung zugänglich

Dinan MA, Curtis LH, Carpenter WR, Biddle AK, Abernethy AP, Patz EF Jr, Schulman KA, Weinberger M (2012) Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2003. J Clin Oncol 30:2725–2730CrossRefPubMed

American Cancer Society Cancer treatment and survivorship, facts and figures 2016-2017. (Last Updated: 2016)

Agostini P, Cieslik H, Rathinam S, Bishay E, Kalkat MS, Rajesh PB, Steyn RS, Singh S, Naidu B (2010) Postoperative pulmonary complications following thoracic surgery: are there any modifiable risk factors? Thorax 65:815–818CrossRefPubMed

Ha D, Choi H, Zell K, Raymond DP, Stephans K, Wang XF, Videtic G, McCarthy K, Minai OA, Mazzone PJ (2014) Association of impaired heart rate recovery with cardiopulmonary complications after lung cancer resection surgery. J Thorac Cardiovasc Surg 149:1168–1173CrossRefPubMed

Win T, Groves AM, Ritchie AJ, Wells FC, Cafferty F, Laroche CM (2007) The effect of lung resection on pulmonary function and exercise capacity in lung cancer patients. Respir Care 52:720–726PubMed

Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, Hagerty KL, Somerfield MR, Vaughn DJ, ASCO Cancer Survivorship Expert Panel (2007) American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 25:3991–4008CrossRefPubMed

Didier KD, Ederer AK, Reiter LK, Brown M, Hardy R, Caldwell J, Black C, Bemben MG, Ade CJ (2017) Altered blood flow response to small muscle mass exercise in cancer survivors treated with adjuvant therapy. J Am Heart Assoc 6:2. https://doi.org/10.1161/JAHA.116.004784 CrossRef

Ederer AK, Didier KD, Reiter LK, Brown M, Hardy R, Caldwell J, Black CD, Larson RD, Ade CJ (2016) Influence of adjuvant therapy in cancer survivors on endothelial function and skeletal muscle deoxygenation. PLoS One 11:e0147691CrossRefPubMedPubMedCentral

Islam KM, Jiang X, Anggondowati T, Lin G, Ganti AK (2015) Comorbidity and Survival in Lung Cancer Patients. Cancer Epidemiol Biomark Prev 24:1079–1085CrossRef

10.

Kenny PM, King MT, Viney RC, Boyer MJ, Pollicino CA, McLean JM, Fulham MJ, McCaughan BC (2008) Quality of life and survival in the 2 years after surgery for non small-cell lung cancer. J Clin Oncol 26:233–241CrossRefPubMed

11.

Sarna L, Evangelista L, Tashkin D, Padilla G, Holmes C, Brecht ML, Grannis F (2004) Impact of respiratory symptoms and pulmonary function on quality of life of long-term survivors of non-small cell lung cancer. Chest 125:439–445CrossRefPubMed

12.

Gralla RJ, Hollen PJ, Msaouel P, Davis BV, Petersen J (2014) An evidence-based determination of issues affecting quality of life and patient-reported outcomes in lung cancer: results of a survey of 660 patients. J Thorac Oncol 9(1243-1248):22

13.

Brunelli A, Kim AW, Berger KI, Addrizzo-Harris DJ (2013) Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: diagnosis and management of lung cancer, 3rd ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143:e166S–e190SCrossRefPubMed

14.

Brunelli A, Charloux A, Bolliger CT, Rocco G, Sculier JP, Varela G, Licker M, Ferguson MK, Faivre-Finn C, Huber RM, Clini EM, Win T, De Ruysscher D, Goldman L, European Respiratory Society and European Society of Thoracic Surgeons joint task force on fitness for radical therapy (2009) ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J 34:17–41CrossRefPubMed

15.

Lim E, Baldwin D, Beckles M, Duffy J, Entwisle J, Faivre-Finn C, Kerr K, Macfie A, McGuigan J, Padley S, Popat S, Screaton N, Snee M, Waller D, Warburton C, Win T, British Thoracic Society, Society for Cardiothoracic Surgery in Great Britain and Ireland (2010) Guidelines on the radical management of patients with lung cancer. Thorax 65(Suppl 3):iii1–ii27CrossRefPubMed

16.

Kasymjanova G, Correa JA, Kreisman H, Dajczman E, Pepe C, Dobson S, Lajeunesse L, Sharma R, Small D (2009) Prognostic value of the six-minute walk in advanced non-small cell lung cancer. J Thorac Oncol 4:602–607CrossRefPubMed

17.

Ha D, Stephens K, Choi H, Zell K, Wang X, Minai O, Raymond D, Videtic G, Mazzone P (2015) Heart rate recovery and survival in patients undergoing stereotactic body radiotherapy for treatment of early-stage lung cancer. JRSBRT 3(3):193–201PubMedPubMedCentral

18.

Ha D, Mazzone PJ, Ries AL, Malhotra A, Fuster M (2016) The utility of exercise testing in patients with lung cancer. J Thorac Oncol 11:1397–1410CrossRefPubMedPubMedCentral

19.

Brunelli A, Xiume F, Refai M, Salati M, Marasco R, Sciarra V, Sabbatini A (2007) Evaluation of expiratory volume, diffusion capacity, and exercise tolerance following major lung resection: a prospective follow-up analysis. Chest 131:141–147CrossRefPubMed

20.

von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, STROBE Initiative (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 147:573–577CrossRef

21.

Schmidt K, Vogt L, Thiel C, Jager E, Banzer W (2013) Validity of the six-minute walk test in cancer patients. Int J Sports Med 34:631–636CrossRefPubMed

22.

Nakagawa T, Chiba N, Saito M, Sakaguchi Y, Ishikawa S (2014) Clinical relevance of decreased oxygen saturation during 6-min walk test in preoperative physiologic assessment for lung cancer surgery. Gen Thorac Cardiovasc Surg 62:620–626CrossRefPubMed

23.

ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111–117CrossRef

24.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC (1993) The European Organization for Research and Treatment 23 of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376CrossRefPubMed

25.

Giesinger JM, Kieffer JM, Fayers PM, Groenvold M, Petersen MA, Scott NW, Sprangers MA, Velikova G, Aaronson NK, EORTC Quality of Life Group (2016) Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust. J Clin Epidemiol 69:79–88CrossRefPubMed

26.

Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M (1994) The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 30A:635–642CrossRefPubMed

27.

Shaw JW, Johnson JA, Coons SJ (2005) US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 43:203–220CrossRefPubMed

28.

Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28:193–213CrossRefPubMed

29.

Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM (1998) Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. Chest 113:619–624CrossRefPubMed

30.

Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, Huber SL (1999) The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 85:1186–1196CrossRefPubMed

31.

Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370CrossRefPubMed

32.

Enright PL, Sherrill DL (1998) Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 158:1384–1387CrossRefPubMed

33.

Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42:377–381CrossRefPubMed

34.

Scott NW, Fayers PM, Aaronson NK, Bottomley A, de Graeff A, Groenvold M, Gundy C, Koller M, Peterson MA, Sprangers MAG (2008) EORTC QLQ-C30 reference values. EORTC Quality of Life Group

35.

Martinez FJ, Foster G, Curtis JL, Criner G, Weinmann G, Fishman A, MM DC, Benditt J, Sciurba F, Make B, Mohsenifar Z, Diaz P, Hoffman E, Wise R, NETT Research Group (2006) Predictors of mortality in patients with emphysema and severe airflow obstruction. Am J Respir Crit Care Med 173:1326–1334CrossRefPubMedPubMedCentral

36.

Deslauriers J, Ugalde P, Miro S, Deslauriers DR, Ferland S, Bergeron S, Lacasse Y, Provencher S (2011) Long-term physiological consequences of pneumonectomy. Semin Thorac Cardiovasc Surg 23:196–202CrossRefPubMed

37.

Cavalheri V, Jenkins S, Cecins N, Gain K, Phillips M, Sanders LH, Hill K (2015) Impairments after curative intent treatment for non-small cell lung cancer: a comparison with age and gender-matched healthy controls. Respir Med 109:1332–1339CrossRefPubMed

38.

Singh SJ, Puhan MA, Andrianopoulos V, Hernandes NA, Mitchell KE, Hill CJ, Lee AL, Camillo CA, Troosters T, Spruit MA, Carlin BW, Wanger J, Pepin V, Saey D, Pitta F, Kaminsky DA, McCormack MC, MacIntyre N, Culver BH, Sciurba FC, Revill SM, Delafosse V, Holland AE (2014) An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease. Eur Respir J 44:1447–1478CrossRefPubMed

39.

Granger CL, Holland AE, Gordon IR, Denehy L (2015) Minimal important difference of the 6-min walk distance in lung cancer. Chron Respir Dis 12:146–154CrossRefPubMed

40.

Granger CL, Denehy L, Parry SM, Martin J, Dimitriadis T, Sorohan M, Irving L (2015) Which field walking test should be used to assess functional exercise capacity in lung cancer? An observational study. BMC Pulm Med 15:89CrossRefPubMedPubMedCentral

41.

Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30CrossRefPubMed

42.

National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365:395–409CrossRef

43.

Wang Z, Hu Y, Wang Y, Han W, Wang L, Xue F, Sui X, Song W, Shi R, Jiang J (2016) Can CT screening give rise to a beneficial stage shift in lung cancer patients? Systematic review and meta-analysis. PLoS One 11:e0164416CrossRefPubMedPubMedCentral

44.

Speck RM, Courneya KS, Masse LC, Duval S, Schmitz KH (2010) An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv 4:87–100CrossRefPubMed

45.

Bade BC, Thomas DD, Scott JB, Silvestri GA (2015) Increasing physical activity and exercise in lung cancer: reviewing safety, benefits, and application. J Thorac Oncol 10:861–871CrossRefPubMed

46.

Soler X, Diaz-Piedra C, Ries AL (2013) Pulmonary rehabilitation improves sleep quality in chronic lung disease. COPD 10:156–163CrossRefPubMed

47.

Silver JK, Baima J (2013) Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil 92:715–727CrossRefPubMed

Titel: Exercise capacity and cancer-specific quality of life following curative intent treatment of stage I–IIIA lung cancer
verfasst von: Duc Ha
Andrew L. Ries
Peter J. Mazzone
Scott M. Lippman
Mark M. Fuster
Publikationsdatum: 10.02.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 7/2018
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-018-4078-4

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Exercise capacity and cancer-specific quality of life following curative intent treatment of stage I–IIIA lung cancer

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2018

Quality of life trajectories during the first year following hematopoietic cell transplantation: an inception cohort study

Sarcopenia in cancer survivors is associated with increased cardiovascular disease risk

Rash management and treatment persistence of cancer patients treated with epidermal growth factor receptor inhibitors in the Truven MarketScan® research database

The relationship between nutritional status and handgrip strength in adult cancer patients: a cross-sectional study

Treatment toxicities and their impact on oral intake following non-surgical management for head and neck cancer: a 3-year longitudinal study

Ameliorative effects of Tai Chi on cancer-related fatigue: a meta-analysis of randomized controlled trials

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie